of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

Chief Accounting Officer — Lyndsey Crennen: Ms. Crennen was promoted to Chief Accounting Officer within the company.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

President and Chief Executive Officer — Gary Owens: Mr. Owens is departing as President and CEO with a transition period.

CEO — Gary Owens: Gary Owens is departing as President and CEO, with Dr. Siddhartha Kadia appointed as the new President and CEO.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT. On August 12, 2025, Mesa Laboratories, Inc. ("the "Company") drew $97 million under its existing Credit Facility. As of the date of this report, $108 million is outstanding under the Credit Facility. The proceeds from the draw were used to fund the settlement of the Company's outstanding convertible notes that matured on August 15, 2025 in accordance with the terms of the indentu…

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

Changes in Registrant ’ s Certifying Accountant. On June 3, 2025, Mesa Laboratories, Inc., (the "Company") was notified that Moss Adams LLP ("Moss Adams"), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP effective on June 3, 2025. The combined audit practices operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the notification of the merger, Moss Adams has resigned as the auditors of the Company and the Audit Committee of the Company…

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

Changes in Registrant ’ s Certifying Accountant. On September 6, 2024, the Audit Committee of the Board of Directors (the “Audit Committee”) of Mesa Laboratories, Inc. (the “Company”) approved the engagement of Moss Adams LLP (“Moss Adams”) as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements as of and for the fiscal year ending March 31, 2025. In connection therewith, the Audit Committee dismissed RSM US LLP (“RSM”) as the Co…

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT . On April 5, 2024, Mesa Laboratories, Inc. (the “Company” “we” “us” or “our”) amended and restated its senior secured credit agreement (the “Credit Agreement”) with a syndicate of banks led by JPMorgan Chase Bank, N.A., as administrative agent. The Credit Agreement has been modified to (among other changes): 1) Allow proceeds from the Credit Facility to be used to redeem some or all of the Company’s 1.375% Convertible Notes due 2025 (the “2025 Notes…

REGULATION FD DISCLOSURE. On April 8, 2024, the Company issued a press release announcing the entry into the Credit Agreement and the repurchases of the 2025 Notes described in

OTHER EVENTS. Immediately following the completion of the amendment and restatement of the Credit Agreement, on April 5, 2024, Mesa entered into separate, privately negotiated purchase agreements (the “Purchase Agreements”) with a limited number of holders of its outstanding 2025 Notes. Pursuant to the Purchase Agreements, the Company will purchase $75.0 million in aggregate principal amount of the 2025 Notes for an aggregate cash purchase price of approximately $71.25 million excluding accru…

MATERIAL IMPAIRMENTS . On April 1, 2024, Mesa Laboratories, Inc. (“Mesa”, the “Company”, “we”, “us” or “our”) concluded that a material charge for non-cash impairment losses related to goodwill and intangible assets is required for the year ended March 31, 2024. As a result, we are disclosing the following information relating to the preliminary unaudited estimate of impairment losses resulting from our annual impairment testing. Goodwill Impairment We expect to record non-cash impairment los…

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

Director — Mark Capone: Mr. Capone was appointed to the Board and Audit Committee, expanding the board size from six to seven members.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

Mesa financed the purchase price of the acquisition, net of a holdback and cash consideration for a portion of the business under regulatory review, with $12.6 million of cash on hand and $65.0 million borrowed under its existing credit facility. The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities under that section, and shall n…

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On October 5, 2023, Mesa Laboratories, Inc. (the “Company”) amended its four-year senior secured credit agreement (the “Credit Agreement”) with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The terms of the original credit agreement, as amended, have not changed, except: 1) The Revolving Commitment has been increased to $125.0 million, from $75.0 million; and 2) Certain administrative amendments h…